Patent ID: 11944602
Assignee: NOVARTIS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 13:
14. The method according to claim 1,
wherein said autoimmune disease is secondary progressive multiple sclerosis;
wherein the maintenance regimen administered in step b) of said method is an immediate release dosage form comprising 2 mg siponimod;
wherein the maintenance regimen administered in step b) of said method is administered once daily;
wherein the initial titration regimen administered in step a) of said method comprises one administration of 0.25 mg siponimod at day 1, one administration of 0.25 mg siponimod at day 2, one administration of 0.5 mg siponimod at day 3, one administration of 0.75 mg siponimod at day 4, one administration of 1.25 mg siponimod at day 5 and one administration of 2 mg siponimod at day 6; and
wherein in the initial titration regimen administered in step a) of said method immediate release dosage forms comprising 0.25 mg, 0.5 mg, 1 mg and 2 mg siponimod are used.